MarketCap
Facebook
X
Telegram
Celsion Corporation Total Current Liabilities | CLSN
Annual Total Current Liabilities Celsion Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.62 M | 4.79 M | 7.39 M | 10 M | 6.77 M | 6.75 M | 7.89 M | 6.11 M | 6.2 M | 8.42 M | 9.35 M | 10.1 M | 4.67 M | 5.01 M | 6.15 M | 6.8 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 M | 4.62 M | 6.94 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Kadmon Holdings, Inc.
KDMN
|
29.5 M | - | - | $ 1.7 B |  USA |
 |
XBiotech
XBIT
|
7.93 M | $ 1.88 | 0.53 % | $ 57.3 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
63.4 M | - | -2.54 % | $ 57.2 M | USA |
 |
Xencor
XNCR
|
95.9 M | $ 36.19 | 6.28 % | $ 2.69 B | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
27.1 M | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
167 M | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
55.8 M | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
8.86 K | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
968 K | $ 1.87 | 0.31 % | $ 3.18 M | USA |
 |
Translate Bio, Inc.
TBIO
|
101 M | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
21.4 M | - | - | $ 1.94 B |  Canada |
 |
Exicure
XCUR
|
3.89 M | $ 0.91 | 2.77 % | $ 5.73 M | USA |
 |
Urovant Sciences Ltd.
UROV
|
30.9 M | - | - | $ 532 M |  Britain |
 |
Acceleron Pharma Inc.
XLRN
|
60.2 M | - | - | $ 10.9 B | USA |
 |
Zogenix, Inc.
ZGNX
|
82.7 M | - | -4.97 % | $ 664 M | USA |
|
Yunhong International
ZGYH
|
523 K | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
18.4 M | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
41.8 M | $ 39.02 | 3.56 % | $ 3.09 B | Canada |
 |
Leap Therapeutics
LPTX
|
4.56 M | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
71.9 M | $ 29.63 | 3.1 % | $ 1.53 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
1.4 M | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
69.5 M | $ 12.73 | -3.67 % | $ 3.03 B | USA |
 |
Cortexyme
CRTX
|
43.2 M | - | -1.05 % | $ 67.1 M | USA |
 |
Daré Bioscience
DARE
|
23.7 M | $ 0.64 | 2.96 % | $ 7.15 M | USA |
 |
Fate Therapeutics
FATE
|
36.1 M | $ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
5.82 M | $ 15.15 | 3.41 % | $ 205 M | USA |
 |
Halozyme Therapeutics
HALO
|
177 M | $ 103.85 | -15.54 % | $ 12.4 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
316 M | $ 15.16 | 6.76 % | $ 13 B | China |
 |
Aptorum Group Limited
APM
|
4.59 M | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
11.7 M | $ 0.74 | 0.77 % | $ 77 M | USA |
 |
Kodiak Sciences
KOD
|
45.5 M | $ 99.33 | 9.13 % | $ 5.29 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
92.1 M | $ 0.05 | -14.81 % | $ 547 | USA |
 |
BioAtla
BCAB
|
21.9 M | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
147 M | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
46.4 M | $ 24.77 | -3.73 % | $ 1.19 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
18.3 M | $ 13.47 | 4.1 % | $ 1.2 B | USA |
 |
ARCA biopharma
ABIO
|
15.4 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
2.15 M | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
12.2 M | - | - | $ 374 | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
6.18 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |